STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.

Overview of Jaguar Health Inc

Jaguar Health Inc (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company that develops innovative, plant-based prescription medicines sustainably derived from rainforest botanical sources. Operating within the natural pharmaceuticals and gastrointestinal therapeutics sectors, the company focuses on non-opioid, anti-secretory agents to address chronic gastrointestinal distress in both human and animal populations. With an emphasis on sustainable practices and fair trade, Jaguar Health harnesses traditional botanical knowledge to deliver solutions for chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain.

Core Business and Product Portfolio

At its core, Jaguar Health is committed to developing novel treatments for overactive bowel conditions. The company is recognized for its pioneering work with crofelemer, a naturally derived anti-secretory agent that exhibits a normalizing effect on the gastrointestinal tract. Mytesi®, for example, is an approved prescription drug providing symptomatic relief for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In addition, Jaguar Health leverages its research through its fully-owned subsidiary, Napo Pharmaceuticals, which is dedicated to broadening the therapeutic reach of these treatments across human health scenarios, including cancers and other complex GI conditions.

Beyond human pharmaceuticals, Jaguar Health applies its expertise to the animal health segment with targeted products. Canalevia™ is a prescription drug candidate aimed at treating various forms of diarrhea in dogs, while Equilevia™ focuses on total gut health in equine athletes. These offerings position the company uniquely by addressing both human and veterinary needs with a unified approach to gastrointestinal wellness.

Scientific and Sustainable Approach

Jaguar Health stands out for its deep commitment to sustainability and scientific innovation. The active compounds are harvested from plants traditionally used in rainforest regions, ensuring ecological integrity and supporting indigenous communities. The company’s research into crofelemer underscores its potential to benefit multiple gastrointestinal disorders through its unique, local anti-secretory mechanism. This scientifically rigorous approach is supported by numerous clinical efforts and trials, demonstrating a profound understanding of complex biological pathways and unmet medical needs.

Market Position and Industry Relevance

Positioned within the competitive natural pharmaceuticals and gastrointestinal markets, Jaguar Health distinguishes itself through its sustainable sourcing, proprietary botanical research, and commitment to addressing neglected gastrointestinal symptoms. Its products are developed to offer significant improvements in patient quality of life and demonstrate a safety profile that supports chronic utilization. The company's diversified segments in both human and animal health provide resilience and stability within a niche market, making it a noteworthy entity for investors and industry analysts seeking depth in biotechnology innovation.

Operational Excellence and Global Reach

Jaguar Health operates across multiple markets with a focus on sustainable, clinically validated therapeutic solutions. Its integrated business model, combining research and commercial expertise via subsidiaries like Napo Pharmaceuticals, allows it to conduct extensive clinical investigations, including proof-of-concept and Phase 2 studies. By embedding traditional botanical wisdom within a modern regulatory framework, Jaguar Health ensures that its therapeutic offerings remain both innovative and aligned with global healthcare standards.

Expertise, Experience, and Trustworthiness

The company’s operations are underpinned by a team of experienced scientists and clinicians who are experts in gastrointestinal research, natural product formulation, and clinical trial management. This multi-disciplinary approach reinforces Jaguar Health's commitment to providing balanced, evidence-based information while upholding the highest levels of expertise and authoritativeness. The emphasis on sustainability and thorough clinical validation further positions Jaguar Health as a trusted source in the pharmaceutical industry.

Conclusion

In summary, Jaguar Health Inc is a pioneering force in the development of natural, plant-based prescription medicines for gastrointestinal distress, serving both human and animal health sectors. Its sustainable sourcing, commitment to scientific rigor, and innovative product portfolio make it a significant player in the natural pharmaceutical landscape. Through strategic research and development, Jaguar Health continues to address unmet medical needs and advance treatment options for chronic gastrointestinal disorders.

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, is sponsoring the National Trans Visibility March (NTVM) starting September 28, 2020. In conjunction with this event, Napo will host a virtual workshop on the gastrointestinal (GI) consequences of HIV on September 30, 2020, led by advocate Marissa Miller. Jaguar focuses on plant-based, non-opioid medicines for GI distress, with its product Mytesi approved for treating noninfectious diarrhea in HIV/AIDS patients. The company emphasizes its commitment to health equity and support for marginalized communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) will host its inaugural Diarrhea Dialogues virtual event on October 20, 2020, from 3:00 PM to 4:30 PM EDT. The event focuses on supportive care for cancer patients, specifically addressing debilitating diarrhea caused by cancer therapies. Esteemed oncologists, patient advocates, and Jaguar executives will participate, discussing the significant impact of diarrhea on treatment and quality of life. Additionally, Napo Pharmaceuticals, a subsidiary of Jaguar, is advancing research on Mytesi (crofelemer) for the relief of therapy-related diarrhea.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.07%
Tags
conferences
-
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) will present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on September 16 at 3:00 PM ET. Founder and CEO Lisa Conte will lead the presentation, which focuses on the company's innovative, plant-based pharmaceuticals for gastrointestinal distress. Institutional investors can register for the conference here to arrange one-on-one meetings with Jaguar.

Jaguar's Mytesi (crofelemer) is FDA-approved for noninfectious diarrhea relief in adults with HIV/AIDS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
conferences
Rhea-AI Summary

Jaguar Health, Inc. (JAGX) announced a third amendment to its accounts receivable purchase agreement with Oasis Capital, LLC, allowing Oasis to purchase an additional $2,329,662.72 in accounts receivable related to the sales of Mytesi drug product. This financing aims to enhance the company's cash flow without diluting shareholder equity.

The agreement entails a purchase price of $990,106.65 and a transaction fee of $5,000. This follows the success of previous tranches and indicates Jaguar's commitment to a stable cash flow positive business strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
none
-
Rhea-AI Summary

Jaguar Health, Inc. (JAGX) announced on September 2, 2020, it has completed transactions boosting its stockholders' equity above $5 million, meeting the Nasdaq Capital Market's initial listing requirement. Previously, the company reported $1,544,000 in equity at the end of June 2020. The transactions involved exchanging shares of preferred stock and issuing common stock, completed on September 1, 2020. These efforts aim to address a prior notification from Nasdaq regarding a breach of listing rules due to insufficient equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.43%
Tags
none
-
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) provided updates on its investigator-initiated trials of crofelemer (Mytesi), a plant-based FDA-approved medication. Trials include: 1) Chronic Idiopathic Diarrhea, with full enrollment expected by 2020 year-end and results by mid-2021; 2) Functional Diarrhea, starting enrollment in Q4 2020 with results also anticipated in Q4 2021; and 3) Diarrhea in HER2-positive breast cancer patients, nearing enrollment completion with results due mid-2021. Mytesi uniquely treats noninfectious diarrhea in HIV/AIDS patients and aims to address significant healthcare costs associated with chronic diarrhea.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
none
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) has submitted the final technical section required by the FDA to seek approval for its oral plant-based drug, Canalevia, aimed at treating chemotherapy-induced diarrhea in dogs. With over 50,000 dogs affected annually, Canalevia would be the first FDA-approved medicine for this condition. The company anticipates conditional approval for both chemotherapy-induced and exercise-induced diarrhea by mid-2021. Jaguar’s subsidiary, Napo Pharmaceuticals, markets Mytesi, another crofelemer-based product for humans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has submitted the final technical section to the FDA for approval of Canalevia, a plant-based drug to treat chemotherapy-induced diarrhea (CID) in dogs. This submission marks a significant step towards potentially becoming the first FDA-approved treatment for over 50,000 affected dogs annually. The filing supports conditional approval under the Minor Use/Minor Species Act. Jaguar also plans to seek approval for treating exercise-induced diarrhea. Canalevia aims to improve comfort and chemotherapy tolerance in dogs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced an amendment to its accounts receivable purchase agreement with Oasis Capital, LLC. This agreement involves the purchase of additional accounts receivable worth $3,152,545 related to Mytesi drug sales. Oasis will pay $1,339,831.83, with a fee of 5.45% on the total amount. The company aims to secure non-dilutive capital to enhance its cash flow. Mytesi is approved for treating noninfectious diarrhea in HIV/AIDS patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
none
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced a second amendment to its accounts receivable purchase agreement with Oasis Capital for the purchase of additional accounts receivable valued at $3,152,545 related to the sales of Mytesi drug product. Following this amendment, the Company will receive $1,339,831.83 after Oasis charges a 5.45% fee. The financing aims to support Jaguar's strategy to secure non-dilutive capital and work towards becoming a cash flow positive business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.04%
Tags
none

FAQ

What is the current stock price of Jaguar Health (JAGX)?

The current stock price of Jaguar Health (JAGX) is $4.37 as of April 4, 2025.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately 3.0M.

What is Jaguar Health Inc's core business?

Jaguar Health Inc focuses on developing novel, plant-based prescription medicines for gastrointestinal distress in both humans and animals. The company leverages sustainable botanical sources to create non-opioid, anti-secretory therapies.

How does Jaguar Health generate its revenue?

The company generates revenue primarily through its human health segment, which includes the commercialization of therapies like Mytesi® for symptomatic relief of noninfectious diarrhea. Additionally, its animal health segment provides targeted treatments for companion and performance animals.

What makes Jaguar Health's products unique?

Jaguar Health develops therapies using sustainably harvested, rainforest-derived botanicals, ensuring ecological integrity and traditional medicinal value. Their products, such as crofelemer-based therapies, offer localized therapeutic effects that address multiple gastrointestinal disorders.

What are some of the company's key products?

Key products include Mytesi®, a prescription drug for relieving chronic noninfectious diarrhea in adults with HIV/AIDS, and other candidates like Canalevia™ for canine diarrhea and Equilevia™ for equine gut health. These products exemplify their dual focus on human and animal health.

How does Jaguar Health incorporate sustainability into its operations?

Jaguar Health sources its active botanical ingredients from rainforest plants using sustainable harvesting practices and fair trade principles. This approach not only ensures high-quality, natural compounds but also supports indigenous communities and preserves ecological integrity.

Who are the target customers of Jaguar Health?

The company's target customers include patients suffering from chronic gastrointestinal disorders, both in human medicine and veterinary care. It also serves healthcare providers and veterinary professionals seeking natural and sustainable therapeutic solutions.

How does Jaguar Health differentiate itself from competitors?

Jaguar Health distinguishes itself through its commitment to sustainable, plant-based research, a diversified product portfolio across human and animal health, and a rigorous clinical approach backed by extensive scientific expertise. Its unique botanical sourcing and innovative formulations set it apart in the natural pharmaceuticals market.

What role does Napo Pharmaceuticals play in Jaguar Health's business?

Napo Pharmaceuticals, a wholly-owned subsidiary of Jaguar Health, is dedicated to developing and commercializing human prescription pharmaceuticals. It plays a crucial role in extending the company’s reach in addressing neglected gastrointestinal symptoms through advanced clinical research and product development.
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

JAGX Stock Data

2.98M
576.85k
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO